This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Nov. 22, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that the company has been recognized with an "Everyday Hero" award from the NephCure Foundation for its "tireless efforts" to advance science and research in the field of nephrology and to also promote educational efforts related to the treatment of proteinuria in patients with kidney disease who are suffering from nephrotic syndrome. The NephCure Foundation is a charity organization committed exclusively to supporting research seeking the cause of the potentially debilitating kidney disease Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome, improving treatment and finding a cure.
"Questcor is honored to have received this recognition from NephCure," said
Steve Cartt, Chief Operating Officer of Questcor. "We feel strongly about supporting research and educational initiatives that will positively impact patients with kidney disease and the nephrology community as a whole. Our flagship product, Acthar, is an FDA-approved prescription medication that is used by an increasing number of nephrologists to induce remission of proteinuria in patients who are suffering from certain types of nephrotic syndrome. We are proud to support the nephrology community through the funding of research, education and other important initiatives."
Henry Brehm, executive director of NephCure, said the organization decided to recognize Questcor because of its support for a patient population that has a significant unmet need. "Questcor has proven through its actions that it is committed to education, assistance and research that strive to improve the quality of life for patients suffering from nephrotic syndrome, until a cure can be found. We applaud their dedication and commitment to our community."
Questcor was honored at NephCure's annual "Countdown for a Cure" fundraiser held on
November 21st in New York City. The event raises money and awareness for its efforts to fund medical research and education programs in the fight against the kidney disease. Since its inception nine years ago, "Countdown To A Cure" has raised over
$3 million for The NephCure Foundation.
About Proteinuria and Nephrotic Syndrome
Proteinuria (excess urinary protein) can be caused by a variety of diseases and disorders of the kidney. A significant deterioration in kidney function can result in very high levels of proteinuria, a condition associated with nephrotic syndrome. Left untreated, nephrotic syndrome may lead to end stage renal disease, which typically requires life-long dialysis treatments. Types of kidney disease that can lead to nephrotic syndrome and end-stage renal disease include:
Idiopathic Membranous Nephropathy (MN)
Focal Segmental Glomerulosclerosis (FSGS)
Minimal Change Disease (MCD)
Membranoproliferative Glomerulonephritis (MPGN)
Lupus Nephritis (LN)
IgA Nephropathy (IgA)
These diseases damage the glomeruli, small blood vessels that work as a filtering system in the kidneys. They normally keep substances that a body needs, such as blood proteins (albumin), while filtering wastes and excess water from the blood and passing them into the urine. But because they're damaged, the kidneys' filtering system cannot properly function. As a result, substances like protein that were previously unable to pass through can now leak or "spill" into a person's urine. This leads to high protein levels in a person's urine, or proteinuria. Because of this condition, an individual's blood lacks the protein necessary to regulate fluid throughout the body.